Evommune, Inc. Increase (Decrease) in Accounts Payable
Evommune, Inc. (EVMN) reported Increase (Decrease) in Accounts Payable of -$2.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Evommune, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $983.00K.
- Evommune, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$3.75M.
- Evommune, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $3.85M, a 34.93% increase year-over-year.
- Evommune, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$97.00K.
- Evommune, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$837.00K, a 112.87% decline from fiscal 2024.
- Evommune, Inc. increase (decrease) in accounts payable for fiscal 2024 was $6.51M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $983.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.77M 10-Q · filed 2026-08-06 | $1.08M derived: sum of 3 quarters · filed 2026-08-06 | $988.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.75M 10-Q · filed 2026-05-07 | $102.00K derived: sum of 2 quarters · filed 2026-05-07 | $5.00K derived: sum of 3 quarters · filed 2026-05-07 | -$3.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.75M derived: sum of 2 quarters · filed 2026-03-05 | -$146.00K derived: sum of 3 quarters · filed 2026-08-06 | -$837.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | -$97.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-11 | -$4.00M derived: sum of 2 quarters · filed 2026-08-06 | -$4.69M 10-Q · filed 2025-12-11 | -$1.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$3.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$4.59M 10-Q · filed 2026-08-06 | -$1.74M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$691.00K 10-Q · filed 2026-05-07 | $2.16M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.51M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $3.65M 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |